[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659579":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":24,"interventions":35,"overallOfficials":13,"centralContacts":43,"locations":13,"responsibleParty":49,"collaborators":13,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":13,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":13,"enrollmentInfo":63,"targetDuration":13,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":13,"overallStatus":73,"whyStopped":13,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":13},{"fullName":5,"class":6},"Chulalongkorn University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of Leptospira infection","Number of leptospirosis cases based on Polymerase Chain Reaction (PCR), culture and Microscopic Agglutination Test (MAT)","1 month",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","CROSSOVER","PREVENTION",{"masking":19,"maskingDescription":13,"whoMasked":20},"TRIPLE",[21,22,23],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[25,30],{"label":26,"type":27,"description":13,"interventionNames":28},"Doxycycline 200 mg weekly dose","EXPERIMENTAL",[29],"Drug: Doxycycline",{"label":31,"type":32,"description":13,"interventionNames":33},"Placebo","PLACEBO_COMPARATOR",[34],"Drug: Placebo",[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":13},"DRUG","Doxycycline","Doxycycline 200 mg weekly",[26],{"type":37,"name":31,"description":31,"armGroupLabels":42,"otherNames":13},[31],[44],{"name":45,"role":46,"phone":47,"phoneExt":13,"email":48},"Sasipha Tachaboon Excellence center for critical care nephrology","CONTACT","66635314464","sasipha.t@chulahospital.org",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Nattachai Srisawat ,M.D.","Principal investigator","100659579","phase-4-these-studies-that-evaluated-the-efficacy-of-antibiotics-for-leptospirosis-treatment-100659579",false,"NCT07865156","These Studies That Evaluated the Efficacy of Antibiotics for Leptospirosis Treatment.","The Study of the Efficacy of Doxycycline for Chemoprophylaxis Acute Leptospirosis Infection During Rainy Season in Thailand","Inclusion Criteria:\n\n* High-risk exposure typically refers to water or soil - particularly wet ground at workplace and\u002For contact with animal water reservoir\n\nExclusion Criteria:\n\n* Body temperature higher than 38 °C\n* Patients were confirmed to have leptospirosis within 3 months\n* Pregnancy or breastfeeding\n* Allergy to doxycycline\n* Cirrhosis Child-Pugh C, acute hepatitis, persistent elevated liver enzymes AST\u002FALT \\> 3 times\n* Doxycycline Interactions: phenytoin, carbamazepine, barbiturates, warfarin methotrexate, cyclosporin",true,"ALL","18 Years",{"count":64,"type":65},1000,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The goal of this randomized controlled trial is to study antibiotic chemoprophylaxis to prevent leptospirosis of high-risk populations.\n\nThe main question it aims to answer is : Does the efficacy of chemoprophylaxis regimens to prevent prevent leptospirosis?",[71,72],"Leptospirosis","Chemoprophylaxis","NOT_YET_RECRUITING","2026-10-05",{"date":76,"type":77},"2026-10-08","ACTUAL",{"date":79,"type":65},"2026-11-01",{"date":81,"type":65},"2027-01-31",{"name":5,"class":6}]